Additionally, CRISPR-Cas9-mediated PD-1, TRAC, and β2M polygenic disruption of CAR-T cells resulted in enhanced anti-tumor activity in preclinical models of human glioblastoma (Choi et al., 2019). The gene discussed is PDCD1; the disease is neoplasm.